montelukast / Generic mfg. - LARVOL DELTA

Safety and Reliability of Isatuximab Subcutaneous On-Body Injector: Results Across the Phase 3 IRAKLIA, Phase 2 IZALCO, and Phase 1B TCD15484 Trials (IMS 2026) - " Pts with RRMM in IRAKLIA (N=263) and the Phase 1b expansion cohort (N=22) received 1400 mg Isa SC OBI plus pomalidomide and dexamethasone (d). In IZALCO, RRMM pts (N=64) received 1400 mg Isa SC OBI + carfilzomib (K)-d...Preinfusion medications included montelukast (C1), steroids, acetaminophen, and H1 antihistamines... These findings support overall low rates of IRRs and ISRs across trials, with >6000 (99.9%) Isa SC OBI injections successfully delivered. Isa SC OBI shows reproducible safety and reliability in IRAKLIA, IZALCO and Phase 1b trials, supporting it as a novel administration option for pts with MM and its potential for future exploration in at-home administration."

Clinical • P1 data • P2 data • P3 data • Hematological Malignancies • Multiple Myeloma

Premedication Use and Infusion-Related Reactions in Patients Treated with Subcutaneous Isatuximab: A Pooled Post Hoc Safety Analysis (IMS 2026) - " Pts with RRMM in IRAKLIA (Isa SC: n=263; Isa IV: n=264) and the Phase 1b TCD15484 trial (Isa SC dose-expansion cohort: n=22; Isa IV: n=12) received 1400 mg Isa SC OBI or 10 mg/kg Isa IV plus pomalidomide and dexamethasone (d). In IZALCO, pts with RRMM (n=74) received 1400 mg Isa SC OBI or manual injection plus carfilzomib (K)-d...Premedications included montelukast (C1 only per protocol), steroids (excluding dexamethasone), acetaminophen, H1 antihistamines, and others...In C2, most pts received 2 unique premedications, acetaminophen (Isa SC: 99.0%; Isa IV: 97.5%) and diphenhydramine (or equivalent) (Isa SC: 91.9%; Isa IV: 93.3%); some pts continued montelukast beyond C1, with use declining each cycle... Isa SC injections without premedication were more frequent than Isa IV injections without premedication, and no IRRs occurred with Isa SC injections delivered without premedications. The results support Isa SC as a safe delivery option with low incidence of IRRs."

Clinical • Retrospective data • Hematological Malignancies • Multiple Myeloma

A Sustainable, Quality-by-Design (QbD) Inspired Spectrofluorimetric Method for the Concurrent Analysis of Cetirizine and Montelukast in COVID-19 and Allergic Rhinitis Combination Therapy. (PubMed, Luminescence) - "The developed methods were applied for MKT and CTZ concurrent determination in laboratory-prepared mixtures simulating tablet formulations. Greenness and practicality were assessed using Eco-Scale, the Complex MoGAPI, AGREE, and BAGI establishing the method as eco-friendly and suitable for routine quality control."

Journal • Allergic Rhinitis • Immunology • Infectious Disease • Inflammation • Novel Coronavirus Disease

SKIPPirr: Premedication to Reduce Amivantamab Associated Infusion Related Reactions (clinicaltrials.gov) - P2 | N=68 | Active, not recruiting | Sponsor: Janssen Research & Development, LLC | Trial completion date: Mar 2027 ➔ Sep 2027

Trial completion date • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

When GERD Is Not GERD: Unmasking Multisite EGID (ACG 2026) - "She was treated with Omeprazole 40 mg twice daily, famotidine 10 mg daily, and montelukast 10 mg daily, though she frequently missed omeprazole doses...Oral open capsule budesonide 9 mg daily was added, with partial symptom improvement...Further, dupilumab achieved symptomatic, laboratory, and endoscopic remission across all involved sites. Figure: Gastric ulcers of index EGD Figure: Duodenal ulcer of index EGD"

Eosinophilia • Eosinophilic Esophagitis • Gastroenterology • Gastroesophageal Reflux Disease • Gastrointestinal Disorder • Immunology • Peptic Ulcer

Celiac Disease Accounting for Poorly Managed Chronic Rhinosinusitis in a Diet Non-Compliant Gluten-Intolerant Patient (ACG 2026) - "In 2024, ENT reevaluated persistent bilateral ear pressure, tinnitus, and recurrent infections, attributing symptoms to allergies despite poor response to antihistamines, intranasal corticosteroids, and montelukast...Persistent positive serologies, genetic susceptibility, iron deficiency anemia, and symptomatic improvement with gluten avoidance supported ongoing CD despite non-diagnostic histology. Clinicians should consider CD in patients with refractory CRS or chronic otologic complaints, particularly when accompanied by gastrointestinal symptoms, nutritional deficits, or other autoimmune features."

Clinical • Celiac Disease • Gastrointestinal Disorder • Hematological Disorders • Immunology • Infectious Disease • Inflammation • Otorhinolaryngology • Respiratory Diseases • Sinusitis • Vertigo

Beyond Steroids: Successful Treatment of Eosinophilic Enterocolitis With Montelukast (ACG 2026) - "Figure: Figure 1. Trend in leukocytosis, eosinophil percentage, and absolute eosinophil count following initiation of montelukast therapy on 10/7/25 through discharge on 10/14/25."

Eosinophilia • Eosinophilic Esophagitis • Gastrointestinal Disorder • Hematological Malignancies • Hepatology • Human Immunodeficiency Virus • Infectious Disease • Vasculitis

A Clinical Trial to Evaluate MK-4208/TERN-701 in Healthy Adult Participants (MK-4208-001/TERN701-1014) (clinicaltrials.gov) - P1 | N=196 | Completed | Sponsor: Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

New P1 trial

Evaluating the Impact of Leukotriene Receptor Antagonists on Postoperative Acute Kidney Injury: A Retrospective Study. (PubMed, Anesth Analg) - "Perioperative use of leukotriene receptor antagonists was not significantly associated with a lower risk of postoperative AKI following oncologic surgery. Further prospective and mechanistic studies are needed to clarify whether leukotriene receptor antagonists exert renoprotective effects in surgical patients."

Journal • Retrospective data • Acute Kidney Injury • Anesthesia • Critical care • Inflammation • Nephrology • Renal Disease

The Effect of Montelukast, a Cysteinyl Leukotriene Receptor-1 Antagonist, on Malignant Melanoma (ADO 2026) - No abstract available

Melanoma • Solid Tumor

Leukotriene Receptor Antagonists Inhibit SLC19A1 and SLC46A1-Mediated Transport of Folic Acid and Antifolates. (PubMed, Chem Biol Interact) - "In vitro studies showed that MK571, montelukast, zafirlukast, and pranlukast concentration-dependently inhibited SLC19A1 and SLC46A1-mediated uptake of folic acid, methotrexate, and pemetrexed, with IC50 values ranging from 2.34 to 31.8 μM for SLC19A1 and 2.79 to 45.4 μM for SLC46A1. Taken together, this study identified LTRAs as novel and potent inhibitors of the key folate transporters SLC19A1 and SLC46A1, and uncovered previously unrecognized transporter-mediated drug-drug interactions between LTRAs and folate-related agents. These findings highlight the necessity of careful clinical monitoring and potential dose adjustments during concurrent administration to ensure therapeutic safety and efficacy."

Journal • Allergic Rhinitis • Asthma • Immunology • Inflammation • Pulmonary Disease • Respiratory Diseases

Pathophysiological Drivers of Mast Cell Activation Syndrome and Implications for Treatment. (PubMed, Fortune J Health Sci) - "Finally, with a thorough understanding of these advanced molecular processes, there are numerous opportunities to be able to apply specialized inhibitors and novel therapies for treating MCAS. With antihistamines remaining the most well-established first-line treatment, the goal is to continue strengthening research in the field through education on the immunology of MCAS and to encourage discoveries that improve diagnostic biomarkers and therapeutic strategies."

Journal

The influence of the cysteinylleukotriene receptor 1 antagonist montelukast on malignant melanoma (ADO 2026) - No abstract available

Melanoma • Solid Tumor

Sleep disorders associated with montelukast in children with respiratory allergy (PubMed, Rev Med Inst Mex Seguro Soc) - "The association showed an odds ratio (OR) of 8.31, p < 0.0001. Montelukast use was associated with the presence of sleep disorders in the studied population."

Journal • Allergic Rhinitis • Allergy • Asthma • CNS Disorders • Immunology • Inflammation • Pediatrics • Psychiatry • Pulmonary Disease • Respiratory Diseases • Sleep Disorder

Preventing Infusion-Related Reactions with Intravenous Amivantamab: Primary Results from SKIPPirr, a Phase 2 Study (IASLC-WCLC 2024) - P2 | "Amivantamab-lazertinib demonstrated efficacy in treatment-naïve and refractory EGFR -mutated advanced non-small cell lung cancer (NSCLC)...Methods : The global SKIPPirr study (NCT05663866) enrolled patients with EGFR -mutated (Ex19del or L858R) advanced NSCLC after disease progression on sequential osimertinib and platinum-based chemotherapy...A Simon’s 2-stage design was used to evaluate prophylactic approaches in 4 cohorts ( Figure 1 ): 4-mg oral dexamethasone twice daily (BID) on C1D-1, 8-mg oral dexamethasone BID on C1D-2, C1D-1, and 1 hour prior to infusion on C1D1, 10-mg oral montelukast once daily from C1D-4 to C1D1, and 25-mg subcutaneous methotrexate as a single dose at some point between C1D-7 and C1D-3...Preliminary estimates from the fully enrolled cohort (n=40) showed 10 IRRs for an incidence rate of 25% on C1D1; further details will be reported at the meeting. Conclusions : Prophylaxis with 8-mg oral dexamethasone resulted in a meaningful reduction in..."

P2 data • Hypotension • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Thoracic Cancer

Comparative effectiveness of pranlukast versus montelukast as add-on therapy to inhaled corticosteroid/long-acting β₂-agonist (ICS/LABA) on asthma exacerbations: a real-world retrospective cohort study (ERS 2026) - "In real-world clinical practice, pranlukast and montelukast showed comparable effectiveness as add-ons to ICS/LABA in preventing asthma exacerbations in adults."

HEOR • Real-world • Real-world evidence • Retrospective data • Asthma • Chronic Obstructive Pulmonary Disease • Immunology • Respiratory Diseases

Obesity-associated difficult-to-control asthma: baseline clinical profile and treatment burden in a randomized weight-management trial (ERS 2026) - "Add-on therapy was frequent (montelukast 77.8%, theophylline 62.2%); azithromycin was more common in IWM (31.8% vs 4.3%, p<0.05). Difficult-to-control asthma with obesity is highly multimorbid and requires near-universal intensive therapy. Higher ICS escalation in UC suggests steroid intensification alone may not address key drivers, supporting integrated weight- and comorbidity-targeted management."

Clinical • Asthma • CNS Disorders • Gastroesophageal Reflux Disease • Genetic Disorders • Immunology • Obesity • Respiratory Diseases

FeNO suppression test in Children with Severe Asthma (ERS 2026) - " Children with SA (requiring high dose of inhaled steroids plus LABA and/or montelukast) with two or more consecutive measurements of elevated FENO (the last at the moment of inclusion)...FST: Children underwent a week of treatment with fluticasone 500 mcg twice a day (MDI with spacer, single inhalation and retention technique) under remote supervision (WhatsApp); on day 8, they repeated FENO measurement and all evaluations... Most of our children with SA and high FENO had a negative FST."

Clinical • Asthma • Immunology • Respiratory Diseases

POST-INFECTIOUS BRONCHIOLITIS OBLITERANS CASES – CLINICAL DATA ANALYSIS (ERS 2026) - "All patients received inhaled fluticasone, montelukast daily, and azithromycin three times a week. After six months of treatment, symptoms resolved in 86,7% of the cases. Conclusion Diagnosis and treatment durations in PIBO can be variable and immunodeficiency can affect clinical presentation and timing of diagnosis."

Clinical data • CNS Disorders • Diabetes • Osteoporosis • Pulmonary Disease • Respiratory Diseases • Sleep Disorder

TP receptor antagonism superior to biosynthesis inhibition for blockade of the prostanoid component in IgE triggered human small airway constriction (ERS 2026) - "Histamine H1 (mepyramine)+CysLT1 (montelukast) receptor antagonism reduced response (Emax 52±6%) The remaining contraction was abolished by COX1 inhibition (FR122047), TXAS inhibition (ozagrel), or TP receptor antagonism (SQ-29548). Selective inhibition of the biosynthesis of the individual prostanoids was associated with shunting and switching between the prostanoids. Clinically, TP receptor antagonism would be preferred to effectively blunt the prostanoid component of the mast cell-driven bronchoconstriction."

Respiratory Diseases

Topical Anti-Inflammatory Therapy and Surgical Avoidance in Pediatric Obstructive Sleep Apnea: A Systematic Review (AAO-HNSF 2026) - "In the longer treatment study, ~21% receiving ICS with montelukast proceeded to surgery versus ~86% without therapy... Topical anti-inflammatory therapy may serve as an initial treatment option for children with mild OSA or SDB and may reduce the need for subsequent surgery, especially with longer treatment duration. Limited long-term follow-up after treatment precludes conclusions regarding sustained benefit or definitive surgical avoidance."

Clinical • Review • CNS Disorders • Obstructive Sleep Apnea • Pediatrics • Respiratory Diseases • Sleep Disorder

Comparative analysis of adverse drug reaction reports for leukotriene receptor antagonists mainly indicated for allergic rhinitis and asthma: a WHO VigiAccess study. (PubMed, Front Med (Lausanne)) - "Real-world evidence from spontaneous-report databases suggests differences in the safety-reporting profiles of montelukast, pranlukast, and zafirlukast. However, under-reporting and incomplete clinical information preclude estimation of incidence or causal inference; these findings should be interpreted as safety signals."

Adverse drug reaction • Journal • Allergic Rhinitis • Asthma • CNS Disorders • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Mental Retardation • Psychiatry • Pulmonary Disease • Respiratory Diseases • Suicidal Ideation

Montelukast attenuates intestinal mucositis induced by 5-fluorouracil via upregulation of HO-1 and PPAR-γ and suppression of TLR4/NF-κB/HMGB1 and caspase-3 pathways. (PubMed, Naunyn Schmiedebergs Arch Pharmacol) - "These pathological changes were associated with suppression of the PPAR-γ and HO-1 antioxidant enzyme, activation of TLR4/NF-κB/HMGB1 signaling, and cleaved caspase-3 activity. MTK treatment significantly ameliorated histopathological alterations, restored mucosal architecture, enhanced HO-1 and PPAR-γ expression, suppressed TLR4/NF-κB/HMGB1 activation, and attenuated apoptosis. In conclusion, MTK protects against 5-FU-induced mucositis, serving as a promising adjunctive treatment for chemotherapy-induced toxicity."

Journal • Mucositis • CASP3 • HMGB1 • PPARA • TLR4

Intrinsic AIE drug nanocrystals enable imaging-guided orchitis theranostics. (PubMed, Mater Today Bio) - "Here, we show that three clinically approved leukotriene receptor antagonists, namely Pranlukast, Zafirlukast, and Montelukast can be transformed into self-reporting, self-delivering, and self-therapeutic nanotheranostics. In a rat model of acute orchitis, AIE imaging reveals efficient testicular accumulation, which correlates with attenuated histopathological damage, restored oxidative stress balance, and downregulation of the TLR4/MyD88/NF-κB and PK2/PKR1 pathways, with no obvious adverse effects on the measured short-term reproductive indices (sperm morphology and testosterone levels) observed within the experimental timeframe. This strategy converts old drugs into minimal-excipient, self-monitoring AIE nanotheranostics for imaging-guided orchitis therapy."

Journal • MYD88 • TLR4

Comparative adjuvant therapy to reduce vancomycin-associated nephrotoxicity in an animal model. (PubMed, Antimicrob Agents Chemother) - "Montelukast only had a marginal effect in vancomycin-treated animals, whereas zileuton significantly delayed nephrotoxicity onset. These findings support further formulation and dose-optimization studies to repurpose zileuton as a renal-protective adjuvant."

Journal • Preclinical • Acute Kidney Injury • Infectious Disease • Nephrology • Renal Disease